MedTest Announces Commercial Availability of Four New “Forensic Use Only” Urine Drug Screening Reagents to Its Broad Test Menu
Nov 10, 2017 - press releases
(Canton, Michigan) MedTest announced the commercial availability of four new “Forensic Use Only” urine drug tests for use on its BS-200, BS-480 and BA-800M Chemistry Analyzers. The addition of these products broadens MedTest’s menu of urine drug screening reagents currently available.
The four new assays are: DRI Fentanyl, CEDIA AB-PINACA (Spice K2), CEDIA UR-144/XLR-11 (Spice K2) and DRI Ethyl Glucuronide.
In the United States, Forensic Use Only products may only be sold to laboratories associated with the criminal justice system as these products have not been cleared by the US Food and Drug Administration (FDA) via the Section 510(k) pre-market notification process. These products are not intended to be used for In Vitro Diagnostic Use and may not be used for medical or diagnostic purposes to identify ailments, dependency or illness. To insure compliance with the FDA regulations for Forensic Use Only products, MedTest will require customers to sign an acknowledgement letter that will be kept on file before these products will be shipped.
Wayne Brinster, CEO of MedTest, stated: “With the emerging focus on the Opioid Crisis in the United States, MedTest is pleased to be able to offer these tests on our scalable chemistry instruments used in criminal justice laboratories. Whether test volume is low or high, MedTest can provide a “right-sized” testing solution that will optimize laboratory operations and provide cost-effective instrument and reagents.”
About MedTest: MedTest is a diagnostics company that provides automated, fast, and cost-effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing. In June 2013, MedTest acquired Pointe Scientific, a company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981. In the fall of 2014, MedTest acquired Clinitox Diagnostix, a company that manufactures and supports drug confirmatory testing via Liquid Chromatography/Mass Spectrometry (LC/MS). In the spring of 2017, MedTest acquired Medical Laboratory Solutions, providing instrument replacement parts, new and re-certified clinical laboratory equipment, in addition to a wide range of cost-effective service programs for commercially available instruments.
For additional information, please contact:
|Debbie Whitehair, MT(ASCP)SC|
|Vice President, Marketing|